Caribou Biosciences, Inc. Common Stock
Veridion Score
Composite trend over time
Why is CRBU moving today?
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CRBU.
CRBU insider activity
Caribou Biosciences, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for CRBU.
CRBU contract awards, year to date.
Public federal awards linked to this ticker.
CRBU lobbying filings, year to date.
Registered lobbying filings matched to Caribou Biosciences, Inc. Common Stock.